In the area of Hong Kong ECM, Mr. Zheng has acted as the international counsel in several landmark Hong Kong IPO projects, including SenseTime Group’s listing in 2021 (China Business Law Review Deals of the Year 2022), Cirrus Aircraft’s listing in 2024 (the second-largest Hong Kong IPO that year), and Zijin Gold International Company Limited’s listing in 2025 (one of the largest Hong Kong IPOs that year).
Projects where Mr. Zheng acted as the international counsel for either the issuer or the underwriters also include: Sunshine Lake Pharma Co., Ltd., Yidu Technology, Stealth BioTherapeutics Corp., Suzhou Kintor Pharmaceuticals, AOBiome LLC, Zhubaijie Network, Cirrus Aircraft, FWD Group, China Reinsurance (Group) Corporation, YiChang HEC ChangJiang Pharmaceutical Co., Ltd., Union Medical Healthcare Limited, Dekon Food and Agriculture, China Hengshi Foundation Company Limited, V3 Group Limited, Australia's largest coal producer - Yancoal Australia, Macau Legend Development Limited, Times Property Holdings Limited, Lingyi iTech, and Dongwei Technology.
In the area of U.S. capital markets, Mr. Zheng has rich experience in prospectus drafting and SEC filings, including quarterly and annual reports, information statements, Form 13-D disclosures, and Form 8-K filings.